In addition to its lead, proprietary Treg program, SBT-77-7101, Sonoma Biotherapeutics is collaborating with Regeneron to advance a pipeline of Treg cell therapies for autoimmune diseases. For more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback